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Abstract
Glioblastoma Multiforme (GBM) is the most aggressive malignant brain tumor and is associated 
with an extremely poor clinical prognosis. One pathologic hallmark of GBM is excessive 
vascularization with abnormal blood vessels. Extensive investigation of anti-angiogenic therapy as 
a treatment for recurrent GBM has been performed. Bevacizumab, a monoclonal anti-vascular 
endothelial growth factor A (VEGF-A), suggests a progression-free survival benefit but no overall 
survival benefit. Developing novel anti-angiogenic therapies are urgently needed in controlling 
GBM growth. In this study, we demonstrate tumor expression of epithelial membrane protein-2 
(EMP2) promotes angiogenesis both in vitro and in vivo using cell lines from human GBM. 
Mechanistically, this pro-angiogenic effect of EMP2 is partially through upregulating tumor 
VEGF-A levels. A potential therapeutic effect of a systemic administration of anti-EMP2 IgG1 on 
intracranial xenografts was observed resulting in both significant reduction of tumor load and 
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decreased tumor vasculature. These results suggest the potential for anti-EMP2 IgG1 as a 
promising novel anti-angiogenic therapy for GBM. Further investigation is needed to fully 
understand the molecular mechanisms how EMP2 modulates GBM pathogenesis and progression 
and to further characterize anti-EMP2 therapy in GBM.
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Introduction
Glioblastoma Multiforme (GBM) is the most common, aggressive malignant brain tumor, 
affecting 3.2 per 100,000 adults each year in the USA. GBMs often present in patients as de 
novo grade IV astrocytoma and less frequently present as a lower grade (I–III) tumor 1. The 
etiology of GBM is poorly understood and the standard-of-care treatment involves maximal 
surgical resection followed by radiation and chemotherapy with temozolomide 2. Despite the 
multimodality treatment, the clinical outcome of GBM patients is extremely poor with a 
median survival of 12 months and a 5-year survival of less than 10% 1. Two features of 
GBM present significant treatment challenges: 1) GBM is highly invasive which makes 
complete surgical resection almost impossible; 2) GBM is highly vascularized with 
abnormal vessels that appear disorganized, are large in diameter with thick basement 
membrane, and have low levels of pericytes 3. The endothelial cells from patients with GBM 
are distinct and carry the same somatic mutations suggesting tumor endothelial cells 
originate from GBM peritumor niche 4,5. While all the factors regulating angiogenesis in 
GBM are not known, one growth factor implicated in promoting GBM malignancy is 
vascular endothelial growth factor A (VEGF-A) 6. Bevacizumab, a monoclonal antibody 
targeting VEGF-A, is currently a first-line treatment for recurrent GBM and shows a 
progression free survival benefit. However, there is no clear overall survival benefit 7,8. 
Thus, a better understanding of GBM vasculature as well as novel anti-angiogenic therapy in 
GBM is urgently needed.
Epithelial membrane protein-2 (EMP2) is a member of the growth arrest specific-3 (GAS-3) 
family of tetraspan proteins. Previously we reported that EMP2 is present in most human 
GBM biopsies and undetectable in normal human brain tissues 9. Furthermore, high EMP2 
levels are associated with poor survival rates implicating it as an important prognostic and 
diagnostic marker. Mechanistically, EMP2 promotes GBM invasive phenotype in part 
through activating integrin-FAK-Src signaling 9. In this study, we further examine the effect 
of EMP2 expression levels on GBM pathogenesis as well as the therapeutic benefit of anti-
EMP2 IgG1 therapy. We demonstrate that EMP2 levels promote GBM neoangiogenesis 
partially through increasing VEGF-A levels. We also show that anti-EMP2 IgG1 antibody 
therapy dramatically reduce intracranial GBM tumor load and vasculature formation in 
tumor tissues. These results strongly support the utilization of EMP2-targeting therapy as an 
alternative anti-angiogenic therapy for GBM patients.
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Materials and Methods
Cell Lines and Reagents
Human GBM cell lines T98, U118 or U87MG (ATCC, Manassas, VA) were cultured in 
DMEM supplemented with 10% fetal bovine serum (Hyclone Cat#30071), 1% glutamine, 
1% penicillin and streptomycin, and 1% sodium pyruvate in a humidified 5% CO2 incubator 
at 37°C. EMP2 expression was stably overexpressed or reduced using methods previously 
described 9. Briefly, EMP2 was stably overexpressed using a retroviral vector encoding 
EMP2 and green fluorescent protein (GFP) or EMP2-GFP fusion protein. EMP2 expression 
was reduced using a lentiviral vector or an EMP2-specific ribozyme (RIBO), and for these 
cell lines an appropriate plasmid or shRNA vector control (CTRL) was used 9. To create 
intracranial tumors, U87MG/EMP2, U87MG/CTRL and U87MG/shRNA were stably 
infected with a lentiviral vector containing firefly luciferase reporter gene (Luc) by the 
UCLA CURE Vector Core Facility. Cells were used within 2 months after resuscitation of 
frozen aliquots and were authenticated by the supplier. Cells were passaged every 2–4 days. 
Human umbilical vein endothelial cells (HUVEC; ATCC) were cultured in VTEC media as 
per manufacturer’s instructions (Lonza, Allendale, NJ) and were used within the first 10 cell 
passages.
Intracranial U87MG Tumor Implantation
All animal experiments were performed in accordance with the Guide for the Care and Use 
of Laboratory Animals by the National Institutes of Health. The protocol was approved by 
the Office of Animal Research Oversight at UCLA. All efforts were made to minimize 
animal suffering. To create intracranial tumors, U87MG/ EMP2/Luc (n=6 mice), U87MG/
CTRL/Luc (n=11 mice), or U87MG/shRNA/Luc cells (n=12 mice) were stereotactically 
implanted into the right frontal lobe of 6–8-week-old female BALB/c athymic nude mice 
(Jackson Laboratory, Bar Harbor, ME) under adequate anesthesia. Specifically, tumor cells 
(1×105 in 2 µl sterile PBS for each mouse) were injected 2.8mm deep into right frontal lobe 
using a 26-gauge Hamilton syringe, 1mm anterior and 1.5mm lateral relative to the 
intersection of the coronal and sagittal sutures on the skull. Animal health was monitored for 
the behavioral and neurological abnormalities as well as weight loss. Tumor burden was 
monitored by bioluminescence imaging using IVIS200 as previously described 9. Images 
were captured from day 1 to day 21 and day 18 imaging post tumor implantation was 
analysed This experiment was performed with 6 animals per group. To ensure the 
reproducibility of the results between the control and knockdown groups, a second 
experiment with another six animals was performed. The results from the first and second 
experiments were combined with one animal excluded due to over-inhalation of isoflurane 
during imaging.
To determine the anti-EMP2 IgG1 therapeutic effect, the EMP2-overexpressing cell line 
U87MG/EMP2/Luc cells (1×105 cells per 2 µl sterile PBS for each mouse) were 
stereotactically implanted into the right frontal lobe of 6–8-week-old female athymic nude 
mice under adequate anesthesia as described above. We have previously described the 
creation of an anti-EMP2 IgG1 antibody10. To ensure consistency among experiments, anti-
EMP2 IgG1 was prepared in bulk by Lake Pharma on a contractual basis according to their 
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standard practices. Each antibody preparation includes a certificate of analysis ensuring the 
size, purity, and affinity of the antibody.
From day 1, mice were intraperitoneally injected with either control vehicle (n=5 mice) or 
anti-EMP2 full-length IgG1 antibody (n=6 mice) twice a week for three weeks. This first 
three anti-EMP2 antibody treatments were administered as 10 mg/kg body weight of mouse 
and last three anti-EMP2 treatments were 20 mg/kg body weight of mouse. Bioluminescence 
images were captured on days 1, 7, 14 and 21 post tumors implantation to monitor tumor 
growth. A two-way analysis of variance was used to determine the difference between 
control and anti-EMP2 IgG1 antibody treatment groups within treatment time course. 
Significance was defined as *p<0.05, ** p<0.001, *** p<0.0001.
Affymetrix RNA Microarray
RNA was extracted from cells that were genetically altered to change EMP2 expression 
levels. U118/EMP2, U118/CTRL or U118/shRNA cell lines were extracted using the Qiagen 
RNA isolation kits as per manufacturer’s instruction (Qiagen Inc, Valencia, CA). Affymetrix 
U133 plus 2.0 microarray (Affymetrix, Santa Clara, CA) was performed in duplicate by 
UCLA Clinical Microarray Core Facility. Briefly, each RNA sample quality was validated 
by measuring absorbance 260/280, and samples in the range of 1.8–2.1 of 260/280 ratio 
were used for cDNA. RNA was converted to cDNA, hybridized onto microarray chips, 
followed by stringent washing and subsequent labeling with probes for automated 
visualization. An average of duplicate samples was taken and the relative abundance of 
specific gene expression was determined among groups. A heat map was created with R 
software (www.r-project.org) to identify differences and pathway analysis was created with 
Ingenuity software (www.ingenuity.com) by the UCLA Clinical Microarray Core Facility.
Immunohistochemistry
After euthanization, mouse brains were harvested and fixed in 10% formalin for 72 hours. 
Coronal cross sections of brain tumors were cut along the implant sites to expose tumors, 
followed by paraffin embedding. Tumor tissues were stained for CD34 to visualize 
endothelial cells 11. Briefly, for antigen retrieval, sections were incubated at 95°C for 20 min 
in 0.1 M citrate buffer, pH 6. CD34 was detected using rabbit anti-human CD34 (Abcam, 
cat#81289) at a dilution of 1:100 at 4 °C overnight followed by visualization using the 
Vector ABC kit (Vector Labs, Burlingame, CA). Tumor sections were also stained with 
Masson’s trichrome in order to visualize the collagen fibers within tumor tissues as per 
manufacturer’s instruction (Polysciences Inc., Warminster, PA).
Image Analysis of CD34 Staining
CD34 staining of tumor tissues was analyzed with Image J software with a custom macro 
script. Specifically, images of CD34 stained vascular endothelia were captured in RGB 
format under 40X magnification and a 1360×1024 resolution using an Olympus BX51 
microscope with a DP72 camera (Olympus Inc., Japan). Images were analyzed using the Fiji 
distribution of NIH ImageJ 12,13. The blue channel had the best contrast ratio and was used 
for all subsequent image analysis steps. Images were segmented by thresholding intensity 
values using Otsu’s method 14. Objects in the resulting binary mask were closed using two 
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passes of dilation followed by two erosions. Any remaining small objects and salt-and-
pepper noise were removed using two erosions followed by two dilations. Masked objects 
were used to measure the area of the original blue channel information. The results were 
tabulated to compared the difference among groups.
HUVEC Migration
2.5×105 T98, U118, U87MG cells that were genetically modified to vary in EMP2 
expression were cultured in 6-well plates for 48 hours. Conditioned media were collected at 
the end of incubation. To determine the biologic effects of cell-secreted angiogenic factors 
into the conditioned media, 1×104 HUVEC cells were plated in the top chamber inserts of 
24-well transwell (Corning Costar, Tewksbury, MA) and conditioned media from the cells 
were added into the bottom wells and the co-culture was incubated at 37°C for 5 hours. The 
filters of inserts were fixed with 3.7% formaldehyde at room temperature for 10 minutes and 
followed by staining with 0.1% crystal violet in 20% methanol at room temperature for 10 
min. The migrated HUVEC cells were visualized using bright field microscopy. Migratory 
cell numbers were averaged by counting four random fields per transwell under 40× 
magnification. The experiment was repeated at least three times.
To determine the effect of the anti-EMP2 IgG1 antibody on cell-secreted angiogenic factors, 
2.5×105 U87MG wild type cells were cultured in 6-well plates in the presence of 50 µg/ml 
anti-EMP2 full-length IgG1 antibody (n=4) or a vehicle control (n=3) for 48 hours. 
Conditioned media were collected at the end of incubation. HUVEC migration assay was 
performed as described above.
HUVEC Tube Formation
Conditioned media were collected as noted above from panels of T98, U118, and U87MG 
cells with varied EMP2 expression levels. Cover slips were placed in 24-well plates and 
coated with freshly thawed cold Geltrex LDEV-free reduced growth factor basement 
membrane matrix (ThermoFisher, Waltham, MA) diluted with ice cold PBS (1:1, vol/vol). 
Geltrex-coated cover slips were solidified at 37°C for 30 minutes and excess liquid was 
removed. 1×105 HUVEC cells were mixed in 500 µl conditioned media and added onto 
Geltrex-coated cover slips. Cells were incubated at 37°C for 16 hours. To visualize HUVEC 
cells, 4 µg/ml calcein (ThermoFisher) was added into cells at 37°C for additional 30 min. 
Tube formation was evaluated under a fluorescent microscope (Olympus BX51) and the 
number of fully formed capillary tubes were counted on the entire cover slips. The 
experiment was performed in triplicate and repeated at least three times.
SDS-PAGE/Western Blots
Cells were lysed in Laemmle sample buffer (62.5 mM Tris-Cl, pH 6.8, 10% glycerol, 2% 
SDS, 0.01% bromphenol blue, 2% β-mercaptoethanol). For detection of EMP2, lysates were 
de-glycosylated as described previously 9. Proteins were separated by SDS-PAGE and 
transferred to nitrocellulose membranes (Amersham Biosciences, Pittsburg, PA). 
Membranes were blocked with 5–10% low fat milk in TBS containing 0.1% Tween-20 and 
probed with polyclonal anti-EMP2 antibody 1:2000, anti-VEGF-A 1:200 (Santa Cruz 
Biotechnology, clone A-20, sc-152, Dallas, TX) and anti-β-actin 1:10,000 (Sigma, A2228, 
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St Louis, MO), anti-phospho-STAT3 1:1000 (Cell Signaling, #9145, Danvers, MA), anti-
STAT3 1:3000 (Cell Signaling, #4904, Danvers, MA), followed by HRP-conjugated 
secondary antibodies (Southern Biotechnology Associates, Birmingham, AL). Protein bands 
were visualized by chemiluminescence (Amersham Biosciences, Pittsburg, PA) and band 
intensities were quantified using NIH Image J software. All experiments were performed at 
least three times.
VEGF-A ELISA
To determine the cell-secreted VEGF-A levels, 2.5×105 T98, U118 or U87MG cells with 
varying EMP2 expressions were cultured in 6-well plates for 48 hours. Conditioned media 
were collected at the end of incubation. Secreted VEGF-A levels in conditioned media were 
examined with human VEGF Quantikine ELISA kit (DVE00, R&D Systems Inc., 
Minneapolis, MN) as per manufacturer’s instruction. Briefly, conditioned media were added 
into 96-well anti-VEGF antibody coated-plates at room temperature for 2 hours. Following 
stringent washing three times, the samples were incubated with conjugated-VEGF antibody 
at room temperature for 2 hours. Following washing three times, substrates were added and 
VEGF-A levels were quantified in comparison with a standard curve using a SpectraMax 
190 microplate reader (Molecular Devices, Sunnyvale, CA). To determine the effect of the 
anti-EMP2 IgG1 antibody on cell-secreted VEGF-A levels, 2.5×105 U87MG wild type cells 
were cultured in 6-well plates in the presence of 50 µg/ml anti-EMP2 full-length IgG1 
antibody (n=4) or a vehicle control (n=3) for 48 hours. Conditioned media were collected at 
the end of incubation. VEGF-A ELISA was performed as noted above. Experiments were 
performed in duplicate and repeated three times.
Statistical Analysis
All values in the text are represented as the mean ± standard error of the mean (SE). 
Differences between means were determined using a one-way, two-way analysis of variance 
or student’s t test as indicated in the figure legends or text. Significance in all cases was 
defined as *p<0.05, ** p<0.001, *** p<0.0001.
Results
EMP2 Promotes GBM Angiogenesis in Intracranial U87MG Tumors
We previously showed that EMP2 overexpression promoted a more invasive phenotype 
while tumors with reduced levels of EMP2 produced smaller, less invasive tumors 9. To 
extend this work, the vasculature of intracranial tumors derived from U87MG cells 
expressing different levels of EMP2 was examined. EMP2 expression was validated by 
Western blots prior to intracranial tumor implantation and increased (6 folds) or reduced (10 
folds) EMP2 levels compared with control cells were stable during the experiments (Fig 
1A). Consistent with previous findings, on day 18 post tumor implantation, reduction of 
EMP2 by shRNA (U87MG/shRNA) significantly decreased intracranial U87MG tumor 
growth compared to control scrambled shRNA (U87MG/CTRL). However, overexpression 
of EMP2 (U87MG/EMP2) did not increase the tumor mass based on bioluminescence 
imaging (Fig 1B).
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Histological examination of the tumors suggested differences in tumor-associated 
vasculature. In order to confirm these effects, brain tumor sections were stained with CD34, 
a marker of endothelial cells. The CD34 staining revealed a striking difference among 
groups with more and larger blood vessels formed in U87MG/EMP2 and fewer, smaller 
blood vessels in U87MG/shRNA compared with U87MG/CTRL intracranial tumors (Fig 
1C, left). Automated quantification using NIH Image J with a custom macro script for CD34 
staining confirmed that U87MG/EMP2 tumors had significantly higher levels of CD34 
staining compared to U87MG/CTRL and U87MG/shRNA (Fig 1D). Concordantly, tumor 
sections were stained with Masson’s trichrome to differentiate tumors from surrounding 
connective collagen tissues and the results confirmed more collegen tissues (in blue) in 
U87MG/EMP2 and less in U87MG/shRNA compared with U87MG/CTRL tumors (Fig 1C, 
right). These data collectively suggest that EMP2 plays an important role in promoting 
angiogenesis and regulating tumor vasculature in GBM tumors in vivo.
EMP2-regulated Angiogenic Factors Potentiate HUVEC Migration and Capillary Tube 
Formation in Vitro
To characterize the effects of EMP2 on angiogenesis in GBM cell lines, in vitro endothelial 
cell functional assays were performed using panels of T98, U118 and U87MG cells which 
expressed different levels of EMP2 and have been previously described 9. Conditioned 
media from panels of T98, U118 and U87MG revealed a significant positive correlation 
between EMP2 levels and HUVEC cell migration using a Boyden-chamber transwell 
migration assay (Fig 2A). To confirm and extend these results, the ability of EMP2 to 
promote capillary tube formation in vitro was determined. In two of the three cell lines, T98 
and U118, conditioned media from cells with higher EMP2 levels enhanced capillary tube 
formation compared with the ones from control cells. In contrast to the other cell lines, 
under normoxic conditions, U87MG cells effectively formed endothelial tubes independent 
of EMP2 expression (Fig 2B). These results suggested that EMP2 levels promote endothelial 
recruitment and in some cases can promote more efficient tube formation.
EMP2 Increases VEGF-A Expression and Secretion in GBM Cells
Several pathways have been implicated in the regulation of angiogenesis in GBM. The best 
characterized angiogenic factor is VEGF-A, which has been shown to be indispensable for 
organ development as well as for growth in a number of tumors 15. Given the evidence that 
EMP2 regulates endothelial cell migration and the critical role of VEGF-A in GBM, its 
expression was characterized in tumor cells with different levels of EMP2. Expression of 
VEGF-A was quantitated from panels of T98, U118 and U87MG normalized to β-actin (Fig 
2C) and cell-secreted VEGF-A levels were determined by ELISA (Fig 2D). In all three cell 
lines, reduction in EMP2 by either ribozyme or shRNA produced a concomitant reduction in 
VEGF-A. Increased EMP2 appeared to directly upregulate VEGF-A in T98 cells but this 
effect was not statistically significant in U118 or U87MG (Fig 2C and 2D). These results 
suggest that EMP2 expression is required for VEGF-A production but perhaps there is a 
threshold beyond EMP2 cannot augment its translation. This also suggests that the increase 
in endothelial cell migration by increased EMP2 may be independent of VEGF-A.
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U118 Affymetrix RNA Microarray
A number of pathways have been shown to modulate neoangiogenesis in GBM 16,17. In 
order to characterize the transcriptional changes induced by modulating EMP2 levels, 
transcriptome profiling was performed using the Affymetrix U133 plus 2.0 Microarray. 
U118 cells were selected as EMP2 levels regulated both endothelial cell migration and 
capillary tube formation in this cell line. RNA from U118/EMP2, U118/CTRL or U118/
shRNA was analyzed for comparison among groups for differential gene expression. The 
Venn diagram detailed gene expression between groups (Fig 3A). Among which 129 genes 
were expressed more than 1.5 fold between groups and 71 genes showed a reciprocal 
regulation between the three cell lines (Sup 1). Heat map analysis of these 129 genes 
displayed the differential gene profiling hierarchy among the three groups (Fig 3B). In 
addition, we performed the pathway analysis using Ingenuity software and identified 217 
pathways that were associated with high EMP2 gene levels (EMP2 vs. CTRL, Sup 2).
EMP2 Regulates STAT3 in Some GBM Cells
In order to focus on the role of EMP2 in neoangiogenesis, pathways linked to GBM 
neoangiogenesis were further validated. Signal transducer and activator of transcription 3 
(STAT3) is a transcriptional factor that modulates a diverse set of cellular functions 
including neoangiogenesis. Moreover, STAT3 activity has recently been implicated in 
driving GBM pathogenesis 18. In order to validate and extend the regulation of STAT3 by 
EMP2, lysates were prepared as above from three GBM cell lines. STAT3 activation was 
determined by measuring its phosphorylation at tyrosine 705 normalized by total STAT3. 
The results showed heterogeneity among GBM cell lines. In panels of T98 and U118 cells, 
overexpression of EMP2 increased activated STAT3 whereas reduction of EMP2 reduced its 
activation compared with control cells. However, in contrast to the other two cell lines, there 
was no effect of EMP2 on STAT3 activation observed in panel of U87MG cells (Fig 3C). 
These results suggest that neoangiogenic signaling can be regulated by multiple pathways 
and may reflect the heterogeneity between different GBM cell lines.
Anti-EMP2 Reduces Intracranial U87MG/EMP2 Tumor Load and Angiogenesis
Our group have previously developed and characterized a humanized monoclonal anti-
EMP2 IgG1 and examined its therapeutic effect in multiple model systems 9,10. To further 
determine the application of this monoclonal antibody treatment in GBM, we established 
intracranial murine models using the more aggressive U87MG/EMP2 tumors. Tumor growth 
was monitored by bioluminescence imaging on day 1, 7, 14 and 21 post tumor implantation. 
Systemic anti-EMP2 IgG1 antibody treatment was initiated from day 1 post implantation. At 
day 14 and 21 we observed a significant reduction of tumor load from anti-EMP2 IgG1-
treated animals compared to control vehicle-treated animals (Fig 4A). At day 21, intracranial 
tumors were collected and the gross histology and vasculature was assessed. Hematoxylin 
and eosin staining showed similar micro-metastases on the margins of the tumor (Fig 4B, 
left top) but significant changes were obtained in the tumor-associated vasculature. CD34 
staining revealed a robust reduction in angiogenesis in anti-EMP2 IgG1-treated animals 
compared to the vehicle control-treated ones (Fig 4B, left bottom). Automated quantification 
of CD34 staining showed a 68.1% reduction in CD34 staining area in anti-EMP2 IgG1-
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treated mice compared with control vehicle-treated mice (Fig 4B, right). These results 
suggest that anti-EMP2 IgG1 may be a novel anti-angiogenic therapy for GBM in this model 
system.
To further elucidate the mechanism of the antibody, U87MG cells were treated with the anti-
EMP2 IgG1 antibody or a vehicle control and conditioned media were collected. HUVEC 
migration assay demonstrated a significant reduction in HUVEC cell recruitment in the 
presence of anti-EMP2 antibody compared with vehicle control (Fig 5A). Concordantly, 
VEGF-A expression in tumor cells (Fig 5B) and cell-secreted VEGF-A levels in conditioned 
media (Fig 5C) were also significantly decreased by treatment of anti-EMP2 IgG1 antibody 
compared with vehicle control. Both in vivo and in vitro studies demonstrated a promising 
therapeutic effect of anti-EMP2 IgG1 antibody in these GBM models that resulted in smaller 
tumor sizes and fewer tumor vasculatures.
Discussion
Despite numerous efforts in the research of GBM pathogenesis and multimodality treatment, 
the prognosis of GBM patients is still very poor 1. In this report we demonstrate that EMP2 
may be a promising therapeutic target due to its high specificity in GBM tumors and its 
effect in regulating multiple downstream targets including neoangiogenesis. EMP2 is present 
in over 90% GBM patient samples from human brain tumor tissue microarray but is absent 
in normal brain, suggesting its utility as a therapeutic and/or diagnostic target for the 
disease 9. GBM tumors exhibit two classical hallmarks. They are typically highly invasive 
into surrounding brain parenchyma as well as excessive vascularization with abnormal blood 
vessels which appear disorganized, large in diameter with thick basement membrane and 
low levels of pericytes. Concordantly, high EMP2 levels in GBM are associated with a more 
invasive phenotype, and an increase in EMP2 by genetic engineering dramatically increased 
tumor invasion 9. In this report, we further demonstrate that engineered, high EMP2 levels 
are associated with both an increase in number as well as size of blood vessels in GBM 
tumors. The effect of altered EMP2 levels on endothelial cells can be recapitulated in vitro 
as cell lines with higher EMP2 levels recruit more endothelial cells and in some cell lines is 
sufficient to induce neovascularization. This regulatory effect is in part due to upregulation 
of VEGF-A levels.
Anti-angiogenic therapies are currently in use as second line therapies for GBM. The FDA 
granted accelerated approval to bevacizumab as a single agent for patients with progressive 
disease, although it results in a progression-free survival benefit, it does not alter overall 
survival for patients with GBM. Recurrence for these patients has been associated with poor 
tumor oxygenation with the resulting bevacizumab resistant glioblastomas showing 
increased c-Met, focal adhesion kinase, and STAT3 phosphorylation 19–21. In contrast to the 
anti-angiogenics on the market, anti-EMP2 therapy alters the tumor cell. Our group has 
previously developed and characterized a humanized monoclonal IgG1 antibody targeting 
EMP2 10, and we examined its therapeutic effect using intracranial U87MG/EMP2 tumor 
xenografts. We find the systemic treatments using anti-EMP2 antibody significantly reduced 
tumor load by bioluminescence imaging and formed less vasculature in tumor tissues, 
suggesting it may be a promising novel anti-angiogenic therapy for GBM.
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Using Affymetrix RNA microarray technology, modulation of EMP2 levels altered several 
signaling pathways. In this report, we focus on the pathways previously implicated in 
regulating neoangiogenesis. STAT3 activation regulates diverse cellular functions including 
neoangiogenesis. Persistent STAT3 phosphorylation is detectable in 70% of human tumors 
and in up to 83% of primary GBM 18. JSI-124, a natural chemical compound and a potent 
STAT3 inhibitor, effectively inhibits VEGF-A expression, prevents HUVEC migration and 
capillary tube formation and also reduces invasiveness of GBM cells 22. In our study, EMP2 
increased STAT3 phosphorylation in T98 and U118 but not in U87MG panels, and we 
predict this discrepancy is likely due to the heterogeneity of molecular backgrounds of GBM 
cell lines. It is well established that GBM cell lines are highly heterogeneous, and this can 
include alterations in p53 and/or PTEN. Tumor suppressor p53 mutation is very common in 
GBM and seen in 25–30% of primary GBM and 60–70% of secondary GBM 23. 
Phosphatase and tensin homolog (PTEN) mutations are observed in up to 40% of GBM 
tumors, and dual inactivation of p53 and PTEN in murine neural stem cells promotes 
undifferentiated tumors 24. It is known, for example, that U87MG has a mutant PTEN but 
wild type p53 and is classified as an epithelial cell line. In contrast, U118 has both mutant 
PTEN and p53 and is characterized as mixed cell line, while T98 is typically characterized 
as a p53 mutant mesenchymal cell 25–27. In this context, it has been shown that STAT3 can 
have varying effects based on PTEN status, where it can act as a tumor suppressor in some 
GBM cell lines with PTEN deficiency 28. We thus predict that signaling from EMP2, a 
membrane protein, is upstream of these mutations, but its effect on STAT3 signaling can 
become more or less dominant depending on the other alterations within the cell. Likewise, 
the downregulation of EMP2 by the antibody inhibits tumor associated VEGF-A production 
with one direct effect being a decrease in VEGF secretion.
Drug delivery is one of the major formidable obstacles in treating GBM and standard 
systemically administered chemotherapy is often insufficient to deliver across intact blood 
brain barrier (BBB). The homeostasis of BBB is essential for normal brain functions. 
Detailed mechanisms of BBB are still elusive, but it is formed by the tight junctions of brain 
capillary endothelial cells surrounded by astrocytes, pericytes and microglial 29. The intact 
BBB prevents passage of water-soluble compounds with a molecular weight greater than 
180 Da; however, most chemotherapeutic agents have molecular weight greater than 200 
Da 30. In GBM, the BBB is compromised and leaky which leads to edematous swelling, 
increased intracerebral pressure, and possible passage of compounds with a greater 
molecular weight 29. In this study, we predict that the anti-EMP2 IgG1 antibody may 
successfully cross the leaky BBB in a compromised state.
In conclusion, our study revealed a novel role for EMP2 in regulating GBM tumor-stromal 
interactions. EMP2 in the tumor promoted endothelial recruitment and vessel formation, and 
this effect could be recapitulated in vivo. We further show that anti-EMP2 IgG1 antibody 
therapy may be a novel anti-angiogenic treatment for GBM through a decrease in tumor-
associated VEGF-A. Additional studies are needed to further translate the effects of the anti-
EMP2 IgG1 to further explore how timing, dose, and other delivery methods (intratumor, 
intrathecal vs. systemic) may improve its utility.
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FIG 1. EMP2 Promotes Angiogenesis in U87MG Intracranial Tumors
(A) EMP2 levels were validated among the U87MG/Luc panel by Western Blots prior to 
stereotactic implantation. (B) Intracranial tumor growth was monitored by bioluminescence 
imaging on day 18 post tumor implantations in mice bearing U87MG/EMP2 (n=6), 
U87MG/CTRL (n=11) or U87MG/shRNA (n=12). The numbers of animals per group was 
generated by pooling two independent trials. (C) Intracranial tumors were fixed and stained 
with CD34 (left) and trichrome (right) and representative images were taken with a bright 
field microscope under 400× magnification. Arrowheads indicate representative staining of 
tumor associated vasculature. (D) Automated quantification of CD34 staining among groups 
was determined by NIH Image J software with a custom macro script as detailed in methods. 
One-way analysis of variance with a Bonferroni post-test was calculated to determine the 
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difference among three groups. Significance was defined as *p<0.05, ** p<0.001, *** 
p<0.0001.
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FIG 2. EMP2 Potentiates HUVEC Migration and Tube Formation and Increases VEGF-A 
Expression and Secretion in vitro
T98, U118 or U87MG cells with different levels of EMP2 were cultured for 48 hours and 
conditioned media were collected at the end of incubation. (A) HUVEC migration assay and 
(B) capillary tube formation were performed as described in methods. Migratory cell 
numbers were averaged by counting four random fields per transwell under 400× 
magnification using a bright field microscope with the averaged results presented. Tube 
formation was evaluated under a fluorescent microscope and all fully formed tubes were 
counted on the entire cover slips. The experiment was repeated three times, and the averaged 
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results presented. (C) T98, U118 or U87MG cells with different levels of EMP2 were 
cultured for 48 hours and cells were lysed to evaluate VEGF-A expression by Western Blots. 
Quantification of VEGF-A expression normalized by β-actin were determined by NIH 
Image J software (top) and representative images of Western Blots show the expression of 
VEGF-A, EMP2, or β-actin (bottom). (D) T98, U118 or U87MG with different levels of 
EMP2 were cultured for 48 hours and conditioned media were collected at the end of 
incubation. Secreted VEGF-A levels in conditioned media were examined by VEGF-A 
ELISA. The experiments were performed in triplicate or duplicate and repeated at least three 
times. One-way analysis of variance with a Bonferroni post-test was calculated to determine 
the difference among three groups. Significance was not reached in U87MG panel by one-
way analysis of variance, a student’s t test was performed between U87MG/EMP2 and U87/
shRNA. Significance was defined as *p<0.05, ** p<0.001, *** p<0.0001.
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FIG 3. U118 Affymetrix RNA Microarray and EMP2 Regulates STAT3 in Some GBM Cells
RNA was extracted from U118/EMP2, U118/CTRL or U118/shRNA. Affymetrix U133 plus 
2.0 microarrays were performed in duplicate and the average of two samples was taken. The 
relative abundance of specific gene expression was determined among groups. (A) Gene 
expression was detailed between groups in a Venn diagram. (B) 129 genes were expressed 
more than 1.5 fold between groups and heat map analysis displayed the differential gene 
profiling hierarchy among three groups using R software. (C) T98, U118 or U87MG cells 
with different levels of EMP2 were cultured for 48 hours and cells were lysed to evaluate 
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total STAT3 expression as well as STAT3 phosphorylation at Y705 by Western Blots. 
Quantification of STAT3 phosphorylation normalized by total STAT3 expression were 
determined by NIH Image J software (top) and representative images of Western Blots 
showed the expression of p-STAT3, STAT3 or β-actin (bottom). The experiments were 
repeated at least three times. One-way analysis of variance with a Bonferroni post-test was 
calculated to determine the difference among three groups. Significance was defined as ** 
p<0.001, *** p<0.0001.
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FIG 4. Anti-EMP2 Reduces Intracranial U87MG/EMP2 Tumor Load and Angiogenesis
U87MG/EMP2/Luc cells were stereotactically implanted into athymic nude mice. From day 
1, mice were intraperitoneally injected with either control vehicle saline (n=5) or anti-EMP2 
IgG1 antibody (n=6) twice a week for three weeks. (A) Bioluminescence images were 
captured on days 1, 7, 14 and 21 post tumors implantation to monitor tumor growth. A two-
way analysis of variance was used to determine the difference between control and anti-
EMP2 antibody treatment groups within the treatment time course. (B) Representative 
histological images (left, top) and CD34 staining (left, bottom) of intracranial tumors from 
two groups were displayed under 40× and 200× magnification, respectively, and staining 
was automated quantification using NIH Image J software with a custom macro script were 
examined (right). Student’s t test was used to determine the difference between the two 
groups. Significance defined as *p<0.05, *** p<0.0001.
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FIG 5. Anti-EMP2 Decreases HUVEC Migration and VEGF-A Expression and Secretion
U87MG wild type cells were cultured in the presence of anti-EMP2 antibody (n=4) or a 
vehicle (saline) control (n=3) for 48 hours. (A) Conditioned media were collected at the end 
of incubation for HUVEC migration assay. Migratory cell numbers were averaged by 
counting four random fields per transwell (left) and representative images of migratory cells 
were shown under 400× magnification (right). (B) Quantification of VEGF-A expression 
normalized by β-actin were determined by NIH Image J software (left) and representative 
images of Western Blots show the expression of VEGF-A, EMP2, or β-actin (right). (C) 
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Quantification of cell-secreted VEGF-A levels were determined by ELISA. The experiments 
were repeated at least three times. Student’s t test was used to determine the difference 
between the two groups. Significance was defined as *p<0.05, *** p<0.0001.
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